Skip to main content Skip to main navigation menu Skip to site footer

Hubungan Rasio Neutrofil Limfosit dengan Derajat Inflamasi dan Agresivitas Prostat


Prostate inflammation is one of the factors that contribute to prostate growth. Serum prostate specific antigen (PSA) is an inflammatory marker that is often used to assess aggressiveness, but has a relatively high price. It takes an inexpensive parameter and can be calculated easily. The design of this cross-sectional analytic observational study to determine the relationship of neutrophil ratio of lymphocytes with inflammatory degrees and prostate aggressiveness. Using secondary data from June to November 2016 with a sample of 31 people with BPH undergoing TURP surgery procedures. The result of correlation analysis using spearman rank ratio of neutrophil lymphocyte with inflammatory degree (P = 0.969) and aggressiveness (P = 0.509) prostate was not significant. While there was a significant relationship between prostate volume (P = 0.002) and PSA (P = 0.022) to degree of aggressiveness of prostate. The ratio of lymphocyte neutrophils can not be used as a biomarker against inflammatory degrees and prostate aggressiveness. But PSA can be used only to know the degree of aggressiveness rather than the degree of prostate inflammation.




  1. Izmirli M, Arikan B, BayazitY,dkk. Associations of Polymorphisms in HPC2/ELAC2 and SRD5A2 Genes with Benign Prostate Hyperplasia in Turkish Men. Asian Pac J Cancer Prev, 2011;12:731-3.
  2. Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, Lipoproteins and the Risk of Benign Prostatic Hyperplasia in Community-dwelling Men. BJU Int, 101: 313–318.Prostate Diseases.Clinical Biochemistry, 2008;47:909–15.
  3. Duarsa GWK, Lesmana R, Mahadewa TGB. High Serum Prostate Specific Antigen as a Risk Factor for Moderate-Severe Prostate Inflammation in Patient with Benign Prostatic Hyperplasia. Bali Med J, 2016;4:148-51.
  4. Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia? EurUrol, 2009;8:879–86.
  5. Mochtar C.A.,Umbas R., Soebadi D.M, dkk. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak ( Benign Prostatic Hyperplasia/BPH) edisi 2. Jakarta, Ikatan Ahli Urologi Indonesia, 2015:1-27.
  6. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Colorectal Cancer.J Surg Oncol, 2015;91:181-4.
  7. Nunez J, Nunez E, Bodi V, dkk. Usefulness of the Neutrophil to Lymphocyte Ratio in Predicting Long-term Mortality in ST Segment Elevation Myocardial Infarction. Am J Cardiol, 2008;101:747-752.
  8. Halazun KJ, Hardy MA, Rana AA, dkk. Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome after Liver Transplantation for Hepatocellular Carcinoma.Ann Surg, 2009;250:141-51.
  9. Tamhane UU, Aneja S, Montgomery D, dkk. Association between Admission Neutrophil to Lymphocyte Ratio and Outcomes in Patients with Acute Coronary Syndrome.Am J Cardiol, 2008;102: 653-657.
  10. Celikbilek M, Dogan S, Ozbakir O, dkk. Neutrophil-Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis. J Clin Lab Anal, 2013;27:72-76.
  11. Chughtai B, Lee R, Te A, Kaplan S. Role of Inflammation in Benign Prostatic hyperplasia. RevUrol, 2011;13:147–50.
  12. Irani J, Levillian P, Gouion JM, Bon D, Dore B, Auben J. Inflammation in benign prostatic hyperplasia: correlation with prostatic specific antigen value. J Urol, 1997;157: 1301-3
  13. Tanik S, dkk,. Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia? Asian Pacific Journal of Cancer Prevention, 2014;15: 6375-77.
  14. Asseldonk BV, Barkin J,Elterman D S. Medical Therapy for Benign Prostatic Hyperplasia: a Review. Canadian Jour Urol, 2015;10: 7-15.
  15. Ozer K et al. 2016. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urologia internationalis, 2016;16:0042–1138.
  16. Wang L, Yang JR, Yang LY, Liu ZT. Chronic Inflammation in Benign Prostatic Hyperplasia: Implications for Therapy.Med Hypotheses, 2008;70: 1021–23.
  17. Ficarra V, Sekulovic S, Zattoni F, Zazzera M, Novara G. Why and how to Evaluate Chronic Prostatic Inflammation. Eur Urol Suppl, 2013;12:110–15.
  18. Kregel KC, Zhang HJ. An Integrated View of Oxidative Stress in Aging: Basic Mechanisms, Functional Effects, and Pathological Considerations. American journal of physiology Regulatory, integrative and comparative physiology, 2007;292: 18-36.
  19. Tezval H,Rettkowski A, Herrmann T, Kuczyk M dkk. 504 Quantification of the Three Ring Model of T Hald in 455 BPH Patients. Eur.Urol, 2010; 9: 176.
  20. Jain P, Shukla SS, Pandey R. Inflammation: Natural Resources and Its Applications. New Delhi: Springer. 2015;13-14.
  21. Fulop T, Larbi A, Exterman M, dkk. Aging, Immunosenescence, and Cancer . In: Rahman I, Bagchi D, editors. Inflammation, Advancing Age and Nutrition 1st Ed. USA: Elsevier. 2014;55-69.
  22. Michaud M, Balardy L, Moulis G, dkk. Proinflammatory Cytokines, Aging, and Age Related Diseases. JAMDA, 2013;30:1-6.
  23. Gandaglia G, Briganti A, Gontero P, dkk. The Role of Chronic Prostatic Inflammation in the Pathogenesis and Progression of Benign Prostatic Hyperplasia (BPH). BJU Int, 2013;112: 432–41.
  24. Roehrborn CG, Bartsch G, Kirby R, dkk. Guidelines for the Diagnosis and Treatment of Benign Prostatic Hyperplasia: a Comparative, International Review. Urology, 2001;58: 642-50.
  25. Lamb AD, Qadam M, Robert S,. CD4+ and CD8+ T-Lymphocyte Scores Cannot Reliably Predict Progression in Patients with Benign Prostatic Hyperplasia. BJU Int, 2011;108: 43-50.

How to Cite

Maha Udiyana, N. D., Kusuma Duarsa, G. W., & Bagus Mahadewa, T. G. (2018). Hubungan Rasio Neutrofil Limfosit dengan Derajat Inflamasi dan Agresivitas Prostat. Medicina, 49(2).




Search Panel

Nyoman Dwi Maha Udiyana
Google Scholar
Medicina Journal

Gede Wirya Kusuma Duarsa
Google Scholar
Medicina Journal

Tjok Gde Bagus Mahadewa
Google Scholar
Medicina Journal